Quick Answer: Generalized skin sensitivity is not a recognized adverse effect in FDA labeling for semaglutide, though injection site reactions occur in 1.4-2.4% of patients using subcutaneous formulations
Based on the significant unmet need in Alzheimers disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutides potential, despite a low likelihood of success, Martin Holst Lange, chief scientific officer at Novo Nordisk said in a press release
If you are obese, you are at risk for major causes of mortality
Another pro-inflammatory target of GLP-1RAs is matrix metalloproteinase-9 (MMP-9), an enzyme that increases BBB permeability and promotes BBB breakdown through proteolytic activity [77]
David Mansour, Dr
This makes it particularly interesting for patients with neurodegeneration, brain injury , or even post-viral cognitive issues